FBT Biotech ETF Tops Category Returns, Outpaces IBB
FBT biotech ETF is up 20.35% YTD and 53.20% over one year, beating category averages and IBB. Its concentrated equal-weight 30-stock portfolio carries a 0.55% expense ratio and $2.9B AUM.
Gilead Sciences
CompanyCompany Profile
Gilead Sciences is a biopharmaceutical company focused on discovering, developing and delivering innovative therapeutics for people with life-threatening diseases. The company says its work spans more than 35 countries and centers on virology, oncology, and inflammation.
- Website
- https://www.gilead.com
- Headquarters
- Foster City, California, USA
- Founded
- 1987
- Stock Ticker
- NASDAQ:GILD
Related News
CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
IBBQ vs IBB: Biotech ETFs Show Strong Returns but High Volatility
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
WHO Launches Clinical Trial for Bundibugyo Ebola Treatments in DRC
WHO has launched the PARTNERS clinical trial testing MBP134 and remdesivir for Bundibugyo virus disease in the DRC. Advisers recommend limiting all candidate Ebola drugs to clinical trials. The outbreak has caused 1,792 confirmed cases and 625 deaths as of July 9.
Amgen Stock Slides 12.6% as Novo Nordisk Holds GLP-1 Lead
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
FDA Grants Priority Review to Gilead's Once-Daily Bictegravir/Lenacapavir HIV Regimen
The FDA has accepted Gilead's New Drug Application for the investigational once-daily HIV regimen bictegravir/lenacapavir and granted priority review, with a PDUFA action date of August 27, 2026. The filing is supported by Phase 3 ARTISTRY-1 and ARTISTRY-2 data showing comparable efficacy in maintaining virological suppression. If approved, BIC/LEN would be the smallest single-tablet regimen for HIV treatment.
Gilead's Lenacapavir Advances: FDA Accepts Weekly Oral PrEP Application, Global Access Expands
The U.S. FDA has accepted Gilead's application for an investigational once-weekly oral lenacapavir for HIV prevention, with a review date set for February 2027. Concurrently, PEPFAR and The Global Fund are expanding access to the twice-yearly injectable version to a total of 3 million people by 2028. Gilead will present new data on both lenacapavir and a novel bictegravir/lenacapavir combination at CROI 2026.
Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates
Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.
Gilead Q1 2026 Sales Rise 5% to $6.9B; Full-Year Revenue Guidance Raised by $400M
Gilead Sciences reported Q1 2026 total product sales of $6.9 billion, up 5% year over year, with HIV revenue growing 10% to $5.0 billion. The company raised its full-year 2026 base business revenue guidance by $400 million to $29.4–$29.8 billion. Non-GAAP diluted EPS was $2.03, up 12%, while the company advanced its oncology and cell therapy pipeline.
FDA Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07763210 |
Lazarus: IT Therapy for ICANS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07746999 |
North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health |
ENROLLING_BY_INVITATION | |
| NCT07719491 |
Study of GS-0415 and How It Works in People With HIV |
NOT_YET_RECRUITING | PHASE1 |
| NCT07708727 |
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment |
RECRUITING | PHASE2/PHASE3 |
| NCT07703878 |
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors |
RECRUITING | PHASE1 |
| NCT07683000 |
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens |
RECRUITING | PHASE3 |
| NCT07682961 |
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy |
RECRUITING | PHASE3 |
| NCT07658976 |
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy |
NOT_YET_RECRUITING | PHASE3 |
| NCT07652359 |
Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care |
RECRUITING | NA |
| NCT07645287 |
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 |
RECRUITING | PHASE2 |